

AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior versions of the claims presented in the application.

1-96. (Cancelled)

97. (Currently amended) A single phase allergy vaccine system kit for treatment of allergy or for alleviating allergy symptoms in a subject comprising:

(a) a plurality of substantially identical, individual, solid, fast dispersing, oral oromucosal dosage forms, said dosage forms comprising an even dose of an allergen, said dose being effective for inducing an immune response specific to said allergen in said subject, to treat said allergy or alleviate said allergy symptoms in said subject in a sealed container, each of said solid oral dosage forms being held in a sealed enclosure and comprising an effective amount of an allergen suitable for oromucosal administration; and

— (b) — each of said solid dosage forms containing the same amount of the allergen.

98. (Currently amended) A kit The allergy vaccine system according to claim 97 wherein said dosage forms are sublingual dosage forms further comprising instructions for using the multiple solid dosage forms.

99. (Currently amended) A kit The allergy vaccine system according to claim 98 [[97]], wherein the said dosage forms comprise a matrix comprising mannitol, starch, gelatine or any combination thereof is a fast-dispersing dosage form.

100. (Currently amended) A kit The allergy vaccine system according to claim 99 [[97]], wherein said gelatine is fish gelatine each of the solid dosage forms are located in individually sealed blisters in a multiple blister pack.

101-102. (Cancelled)

103. (Currently amended) A kit The allergy vaccine system according to claim 97 [[101]], wherein said dosage forms are non-compressed dosage forms the gelatine is fish gelatine.

104. (Currently amended) A kit The allergy vaccine system according to claim 103 [[97]], wherein said dosage forms are lyophilized dosage forms the effective amount of allergen is between about 2.5 μ g—about 3.75 mg extract/solid dosage form.

105-129. (Cancelled)

130. (Currently amended) The allergy vaccine system according to claim 97 wherein said allergen is a major allergen A multiple dose set of pharmaceutical products suitable for oromucosal administration to a mammal, said products being fast-dispersing solid dosage forms comprising:

_____ a matrix suitable for fast-dispersion upon oromucosal administration; and
2.5 μ g to about 75 μ g of a major grass pollen allergen selected from the group consisting of grass group 1 allergen, grass group 2/3 allergen, grass group 5 allergen and grass group 6 allergen, each dose containing the same amount of allergen.

131. (Currently amended) The allergy vaccine system according to claim 130 wherein said major allergen is selected from the group consisting of grass group 1, grass group 2/3, grass group 5 and grass group 6 allergens A multiple dose set of pharmaceutical products suitable for oromucosal administration to a mammal, said products being fast-dispersing solid dosage forms comprising:

_____ a matrix suitable for fast-dispersion upon oromucosal administration; and
_____ an allergen in an amount sufficient to induce an allergen specific immune response to said allergen in said mammal, each dose containing the same amount of allergen.

132-194. (Cancelled)

195. (Currently amended) The allergy vaccine system according to claim 97 kit of claim 193 wherein said oral dosage forms has have a potency of between about 65 and about 17,600 BAU of said allergen.

196. (Currently amended) The allergy vaccine system according to claim 130 kit of claim 193-wherein each of said oral dosage forms comprise comprises between about [[0.25]] 0.05 μg to about [[375]] 500 μg of said major allergen.

197. (Currently amended) The allergy vaccine system according to claim 131 wherein said dosage forms comprise between about 0.05 μg to about 500 μg of said major allergen kit of claim 193 wherein the major allergen is a grass pollen allergen.

198. (Currently amended) The allergy vaccine system according to claim 97 wherein said allergen is in a form selected from the group consisting of an allergen extract, a purified allergen, a modified allergen, a recombinant agent, and a recombinant mutant allergen kit of claim 197 wherein the grass pollen allergen comprises from about 0.25 μg to about 375 μg of a member selected from the group consisting of grass group 1 allergen, grass group 2/3 allergen, grass group 5 allergen and grass group 6 allergen.

199-219. (Canceled)

220. (Currently amended) The kit allergy vaccine system of claim 198 wherein said dosage forms comprise said allergen extract 97-wherein each of said oral dosage forms have a potency of between about 65 and about 17,600 BAU.

221-232. (Canceled)

233. (Currently amended) The kit allergy vaccine system of claim 97 wherein each of the said dosage forms further comprise comprises at least one anti-allergic drug.

234. (Canceled)

235. (Currently amended) The kit allergy vaccine system of claim 220 wherein said dosage forms comprise about 0.5 μ g to about 5 mg of said allergen extract 97 wherein each of the dosage forms are free of an added compound that functions as an adjuvant when the product is administered to the mammal.

236-242. (Canceled)

243. (Currently amended) The kit allergy vaccine system of claim 97 wherein the said allergen is selected from the group consisting of grass pollen allergen, birch pollen allergen, tree pollen allergen, weed pollen allergen, herb pollen allergen, and ragweed pollen allergen.

244. (Canceled)

245. (New) A vaccine kit for desensitizing a subject to an allergen without an up-dosing period comprising a compartmentalized packet comprising a plurality of separate compartments comprising substantially identical, individual, solid, fast dispersing, unit dosage forms for oromucosal administration, each of said unit dosage forms comprising an even dose of said allergen in an amount effective to induce an allergen specific immune response to said allergen in said subject without up-dosing.

246. (New) The vaccine kit of claim 245 wherein said unit dosage forms are sublingual dosage forms.

247. (New) The vaccine kit of claim 245 wherein said unit dosage forms are non-compressed dosage forms.

248. (New) The vaccine kit of claim 245 wherein said unit dosage are lyophilized dosage forms.

249. (New) The vaccine kit of claim 248 wherein said unit dosage forms comprise a matrix comprising mannitol, starch, gelatine or any combination thereof.

250. (New) The vaccine kit of claim 249 wherein said gelatine is fish gelatine.

251. (New) The vaccine kit of claim 245 wherein said allergen is a major allergen.

252. (New) The vaccine kit of claim 251, wherein said major allergen is selected from the group consisting of grass group 1, grass group 2/3, grass group 5 and grass group 6 allergens.

253. (New) The vaccine kit of claim 245 wherein said dosage forms have a potency of between about 65 and about 17,600 BAU of said allergen.

254. (New) The vaccine kit of claim of claim 251 wherein said dosage forms comprise between about 0.05 μ g to about 500 μ g of said major allergen.

255. (New) The vaccine kit of claim of claim 252 wherein said dosage forms comprise between about 0.05 μ g to about 500 μ g of said major allergen.

256 (New) The vaccine kit of claim 245 wherein said allergen is in a form selected from the group consisting of an allergen extract, a purified allergen, a modified allergen, a recombinant agent, and a recombinant mutant allergen.

257. (New) The vaccine kit of claim 256 wherein said dosage forms comprise said allergen extract.

258. (New) The vaccine kit of claim 257 wherein said dosage forms comprise between about 0.5 μ g to about 5 mg of said allergen extract.

259. (New) The vaccine kit of claim 245 wherein said dosage forms further comprise at least one anti-allergic drug.

260. (New) The vaccine kit of claim 245 wherein the allergen is selected from the group consisting of grass pollen allergen, birch pollen allergen, tree pollen allergen, weed pollen allergen, herb pollen allergen, and ragweed pollen allergen.

261. (New) A single phase, up-dosing free pharmaceutical dosage kit for self administration of an anti-allergy, desensitization therapy for a human subject in need thereof, said kit comprising:

a plurality of substantially identical, individual, solid, fast dispersing, oromucosal dosage forms for safe self administration by said subject,

each of said dosage forms comprising a substantially identical dose of an allergen in an amount effective for inducing an immune response specific to said allergen in said subject.